GYKI 52466 dihydrochloride B

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

GYKI 52466 dihydrochloride 是一种具有口服活性、高选择性和非竞争性的 AMPA/Kainate 受体拮抗剂，其 IC50 值分别为 7.5 和 11 μM。GYKI 52466 dihydrochloride 具有良好的血脑屏障通透性和抗惊厥作用，可用于帕金森病的研究。

GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research.

GYKI 52466 (0.3-100 μM) inhibits inward currents activated by AMPA and Kainate receptor in cultured rat hippocampal neurons.

GYKI 52466 (intraperitoneal injection; 1.76-13.2 mg/kg; once) treatment provides potent anticonvulsant protection against sound-induced seizures in DBA/2 mice.Animal Model:Male and female DBA/2 mice tested for sound-induced seizure responses Dosage:1.76-13.2 mg/kg Administration:Intraperitoneal injection; 1.76-13.2 mg/kg; once Result:Observed Maximal anticonvulsant protection after the i.p. treatment (5-15 min ).

——

Neuroscience

GluR

GluR

——

——

2319722-40-0

366.24

C17H17Cl2N3O2

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 2.78 mg/mL (7.59 mM; 超声助溶 (<60°C)

CC1=NN=C(C2=CC=C(N)C=C2)C3=C(C=C4OCOC4=C3)C1.Cl.Cl

——

(-20℃)

With Ice Pack

≥ 2 years